Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | TAS2R8 | Q9NYW2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879521 | 0.90 | GAA (0.38) | GAATAS2R8ALDH1A1PARP1CYP1A2 | |
| SCHEMBL13879589 | 0.84 | KDM4E (0.37) | GAATAS2R8ALDH1A1PARP1CYP1A2 | |
| SCHEMBL13879416 | 0.77 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL13879520 | 0.76 | NPSR1 (0.52) | GAAALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL13879412 | 0.75 | TAS2R8 (0.42) | TAS2R8ALDH1A1CYP2C19MEN1KMT2A | |
| SCHEMBL13879448 | 0.72 | LMNA (0.38) | TAS2R8PARP1 | |
| SCHEMBL13879406 | 0.71 | AR (0.44) | ALDH1A1MEN1KMT2A | |
| SCHEMBL13879403 | 0.69 | GAA (0.56) | GAATAS2R8ALDH1A1CAPN1PARP1 | |
| SCHEMBL13879543 | 0.69 | GAA (0.53) | GAATAS2R8ALDH1A1CAPN1CYP1A2 | |
| SCHEMBL13879573 | 0.68 | GAA (0.78) | GAATAS2R8ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | GAA 463/4885TAS2R8 4662/4885ALDH1A1 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.